Respiratory Disease Testing Market Size By Test Type (Mechanical Tests {Spirometry, Peak-flow Test, Pulmonary Function Test, Blood Gas Test), Imaging Tests {X-ray, CT-scan, Ultrasonography, MRI}, In-vitro Diagnostic Tests {Point-of-care Test, Molecular Diagnostic Test}), By Application (Chronic Obstructive Pulmonary Disease, Lung Cancer, Asthma, Tuberculosis) By End-use (Diagnostic Centers, Hospitals, Clinics), Industry Analysis Report, Regional Outlook, Application Potential, Competitive Market Share & Forecast, 2020 – 2026

Published Date: Apr 2020  |  Report ID: GMI1871  |  Authors: Sumant Ugalmugale, Rupali Swain

Report Format: PDF   |   Pages: 200   |   Base Year: 2019




Summary Table of Contents Industry Coverage Methodology

Industry Trends

Respiratory Disease Testing Market size was over USD 10 billion in 2019 and shall exhibit close to 8.5% CAGR throughout the forecast timespan. Respiratory disease testing is widely used to measure lung disorders by measuring the capacity to hold, move air and to absorb oxygen. The industry growth is attributed to the rise in respiratory diseases such as chronic obstructive pulmonary disease (COPD), asthma, tuberculosis, and COVID-19 among others.
 

Respiratory Disease Testing Market

Get more details on this report - Request Free Sample PDF
 

Rise in incidence of COVID-19 has led to patient suffering from respiratory distress, thereby increasing the demand for respiratory disease testing. According to World Health Organisation (WHO), till 15th March 2020, approximately 3,204 deaths were registered in China due to COVID-19 outbreak. These cases were associated with severe acute respiratory syndrome (SARS) and thus resulted in increased respiratory disease testing across China. Also, the adoption of imaging technologies in developed as well as developing regions has increased in the past few years.
 

Respiratory Disease Testing Market Report Coverage
Report Coverage Details
Base Year: 2019 Market Size in 2019: 10.13 Billion (USD)
Historical Data for: 2015 to 2019 Forecast Period: 2020 to 2026
Forecast Period 2020 to 2026 CAGR: 8.5% 2026 Value Projection: 18.23 Billion (USD)
Pages: 200 Tables, Charts & Figures: 432
Geographies covered (23): U.S., Canada, Germany, UK, France, Italy, Spain, Switzerland, Netherlands, Japan, China, India, Australia, South Korea, Malaysia, Brazil, Mexico, Argentina, Chile, South Africa, Saudi Arabia, Turkey, Egypt
Segments covered: Test Type, Application, End-use and Region
Companies covered (12): Becton Dickinson & Company, Koninklijke Philips N.V., ResMed, Fischer & Paykel, Medtronic, CAREstream Medical, Ltd., Abbott Laboratories, Thermo Fisher Scientific Inc., Biomérieux, Cosmed, Seegene Inc. and Sdi Diagnostics
Growth Drivers:
  • Rising prevalence of COVID 19 infection
  • Increasing incidence of respiratory diseases
  • Surge in tuberculosis and hospital acquired infections
  • Technological advancements in imaging modalities
Pitfalls & Challenges:
  • Rise in laboratory testing costs
  • Lack of awareness

Get more details on this report - Request Free Sample PDF
 

Recent surge in coronavirus cases globally together with the rise in geriatric population will boost the market growth

The growing coronavirus cases especially in the countries such as the U.S., Italy, Spain, South Korea, and Japan among others has resulted in the increased respiratory disease testing across various healthcare settings. For instance, as of March 17th, 2020, there were a total 2.1 million cases globally. Also, total deaths related to COVID 19 were around 144,221 and around 80% of the individuals were aged 60 and over. Geriatric population are more susceptible to various illnesses such as cardiovascular diseases, diabetes, and respiratory disorders. Thus, routine use of respiratory diagnostic devices among the geriatric population will drive the respiratory disease testing market growth.
 

Increasing adoption of pulmonary and spirometry test for efficient diagnosis

Respiratory Disease Testing Market Share

Get more details on this report - Request Free Sample PDF
 

Mechanical tests segment was valued around USD 3.2 billion in 2019 and is estimated to grow significantly during 2020 to 2026. The major factors boosting the market growth are increasing number of chronic and infectious disease coupled with rising rate of air pollutants and hazardous gases. For instance, as per the Asthma and Allergy Foundation of America (AAFA), approximately 25 million individuals suffer from asthma in the U.S. alone. Asthma is one of the most common diseases among children and affects 14% of children globally.
 

Spirometry test is considered to be of significant importance as it measures vital capacity as well as forced expiratory volume in less than one second. Thus, spirometry segment is expected to register a higher CAGR during the forecast period due to its efficacy and accuracy in diagnosis.
 

Increasing consumption of tobacco smoke and exposure to outdoor pollutants

Respiratory Disease Testing Market Applications

Get more details on this report - Request Free Sample PDF

 

COPD segment held the largest revenue in 2019 and is projected to expand at 9.1% CAGR during 2020 to 2026 due to increasing prevalence of COPD cases globally. Increasing consumption of cigarettes by individuals will eventually lead to respiratory disorders, thereby creating the need for respiratory disease testing. Additionally, increasing R&D investment to develop the advanced treatment options for COPD will further offer various opportunities, thereby augmenting the respiratory disease testing market growth.
 

Availability of advanced imaging modalities in hospitals will boost the global market growth

Hospitals held a significant application share in 2019 and was valued at USD 3.7 billion. Hospitals are well equipped with advanced imaging modalities such as CT-scan, X-ray and MRI machines. Thus, increased adoption of imaging modalities for diagnostic purposes in hospitals will further drive the segmental growth.
 

Moreover, increasing number of COVID-19 cases will further boost the demand of respiratory disease testing in hospitals. For instance, as per the European society of anaesthesiology, by 20 March 2020, the rate of increase in number of patient suffering from COVID-19 were peaked at high level in Italy. Furthermore, these imaging devices have greater significance in outpatient and emergency departments as a preferred diagnostic tool for various types of diseases.
 

High prevalence of chronic and infectious diseases in North America

Prevalence of various chronic and infectious diseases in the North America region is one of the key factors responsible for regional growth. Increasing prevalence of COVID-19 infection will serve as major impact rendering factor for market growth. Till 17th April 2020, approximately 6.7 million cases of COVID-19 were registered in U.S. Majority of active cases are been diagnosed with respiratory illness such as coughing and sneezing. Furthermore, well developed healthcare infrastructure, robust distribution channel for diagnostic devices and increased awareness levels will drive the respiratory disease testing industry growth in the region.
 

Implementation of various strategies such as new product launch and collaborations is expected to create profitable opportunities

Some of the prominent players operating in the respiratory disease testing market include Becton Dickinson & Company, Koninklijke Philips N.V., ResMed and Fischer & Paykel, among others. These major industry players are focusing on various inorganic and organic strategies to launch new devices and mergers & acquisitions to sustain market growth and competition.
 

Recent industry developments:

  • In March 2020, Abbot received Emergency Use Authorization (EUA) from U.S. FDA for ID NOW platform. The device is used as molecular point-of-care test to detect novel coronavirus symptoms such as influenza, respiratory syncytial and strep throat. Thus, introduction of novel products will result in the increased sales revenue for the company.
     
  • In March 2020, Medtronic launched two solutions designed to monitor the patients suffering from COVID-19 and their respiratory symptoms. The virtual care evaluation and monitoring solutions are also made available to the health plans, employers, and U.S. health systems. Thus, the company would benefit from aforementioned solution’s sales.
     

The respiratory disease testing market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2015 to 2026, for the following segments:

By Test type

  • Mechanical Tests
    • Spirometry
    • Peak-flow Test
    • Pulmonary Function Test
    • Blood Gas Test
    • Others
  • Imaging Tests
    • X-ray
    • CT-scan
    • Ultrasonography
    • MRI
  • In-vitro Diagnostics Tests
    • Point-of-care Test
    • Molecular Diagnostic Test
    • Others

By Application

  • Chronic Obstructive Pulmonary Disease
  • Lung Cancer
  • Asthma
  • Tuberculosis
  • Others

By End-use

  • Diagnostic Centres
  • Hospitals
  • Clinics
  • Others

The above information is provided for the following regions and countries:

  • North America
    • U.S.
    • Canada
  • Europe
    • UK
    • Germany
    • Italy
    • Spain
    • France
    • Netherlands
    • Switzerland
  • Asia Pacific
    • India
    • China
    • Japan
    • Australia
    • South Korea
    • Malaysia
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Chile
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • Turkey
    • Egypt

 

Frequently Asked Questions (FAQ) :

The market size of respiratory disease testing exceeded USD 10 billion in 2019.
The industry share of respiratory disease testing is projected to grow at 8.5% CAGR during 0020 to 2026.
COPD application held the largest revenue in 2019 and is projected to expand at 9.1% CAGR during 2020 to 2026 due to increasing prevalence of COPD cases globally.
Mechanical tests segment was valued around USD 3.2 billion in 2019.
Prevalence of various chronic and infectious diseases in the North America along with increasing prevalence of COVID-19 infection is one of the key factors responsible for regional growth.

Buy Now

Need a Discount? Get in touch with us for special pricing

Request Discount

Connect with our sales team

Premium Report Details

  • Published Date: Apr 2020
  • Pages: 200
  • Tables: 406
  • Charts / Figures: 26
  • Companies covered: 12
  • Countries covered: 23

Benefits of Association

Data Coverage & Quality

GMI reports provide the most comprehensive coverage of any focus industry, ensuring a holistic and deep understanding of the market, along with actionable and granular data. We also take pride in our commitment to quality and strive to ensure that our clients get their moneys worth.

Client Trust & Security

GMI maintains strict code of conduct as a business and is committed to ensure that the privacy and trust of our clients are always maintained. As an organization, we also strive to be fully compliant with privacy laws, PCI and information security guidelines.

Customer Service

Our customers rely on us to produce accurate, reliable and timely information. Service orientation is a key mission for us as an organization; our process is guided by the desire to ensure that our clients are provided the best possible solutions in optimal timeframe. GMI stands by its commitment to service, providing timely assistance in both pre-sales and post-sales support for our clients.

GMIPulse, our report store

We have introduced ‘GMIPulse’, which is our report store; designed to offer clients a one-stop platform for all market research and business intelligence requirements. Clients can access reports, presentations, raw data excel sheets as well as detailed company profiles. GMIPulse allows you to track relevant industries and stay informed with latest innovation, competitive and regulatory developments to help design strategic framework.

Chat with us
We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies. More info X